메뉴 건너뛰기




Volumn 12, Issue 2, 2005, Pages 120-126

Multicentre versus single centre approach to rare diseases: The model of systemic light chain amyloidosis

Author keywords

Amyloidosis; Myeloma; Prognosis; Rare diseases; Survival

Indexed keywords

ALKYLATING AGENT;

EID: 22144489896     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.1080/13506120500107055     Document Type: Article
Times cited : (46)

References (13)
  • 1
    • 0028970456 scopus 로고
    • Primary systemic amyloidosis: Clinical and laboratory features in 474 cases
    • Kyle RA, Gertz MA. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.
    • (1995) Semin Hematol , vol.32 , pp. 45-59
    • Kyle, R.A.1    Gertz, M.A.2
  • 2
    • 0030895545 scopus 로고    scopus 로고
    • A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine
    • Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, et al. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202-1207.
    • (1997) N Engl J Med , vol.336 , pp. 1202-1207
    • Kyle, R.A.1    Gertz, M.A.2    Greipp, P.R.3    Witzig, T.E.4    Lust, J.A.5    Lacy, M.Q.6
  • 3
    • 0030682237 scopus 로고    scopus 로고
    • Amyloidosis: A review of recent diagnostic and therapeutic developments
    • Gillmore JD, Hawkins PN, Pepys MB. Amyloidosis: A review of recent diagnostic and therapeutic developments. Br J Haematol 1997;99:245-256.
    • (1997) Br J Haematol , vol.99 , pp. 245-256
    • Gillmore, J.D.1    Hawkins, P.N.2    Pepys, M.B.3
  • 4
    • 0033630225 scopus 로고    scopus 로고
    • The systemic amyloidoses: An overview
    • Falk RH, Skinner M. The systemic amyloidoses: An overview. Adv Intern Med 2000;45:107-137.
    • (2000) Adv Intern Med , vol.45 , pp. 107-137
    • Falk, R.H.1    Skinner, M.2
  • 5
    • 0028936196 scopus 로고
    • Treatment of primary amyloidosis
    • Merlini G. Treatment of primary amyloidosis. Semin Hematol 1995;32:60-79.
    • (1995) Semin Hematol , vol.32 , pp. 60-79
    • Merlini, G.1
  • 6
    • 0031913337 scopus 로고    scopus 로고
    • The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement
    • Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998;91:141-157.
    • (1998) QJM , vol.91 , pp. 141-157
    • Dubrey, S.W.1    Cha, K.2    Anderson, J.3    Chamarthi, B.4    Reisinger, J.5    Skinner, M.6
  • 8
    • 9144269708 scopus 로고    scopus 로고
    • High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study
    • Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study. Ann Intern Med 2004;140:85-93.
    • (2004) Ann Intern Med , vol.140 , pp. 85-93
    • Skinner, M.1    Sanchorawala, V.2    Seldin, D.C.3    Dember, L.M.4    Falk, R.H.5    Berk, J.L.6
  • 9
    • 0025884025 scopus 로고
    • The predictive value of bone marrow morphologic characteristics and immunostaining in primary (AL) amyloidosis
    • Wu SS, Brady K, Anderson JJ, Vezina R, Skinner M, Neiman RS, et al. The predictive value of bone marrow morphologic characteristics and immunostaining in primary (AL) amyloidosis. Am J Clin Pathol 1991;96:95-99.
    • (1991) Am J Clin Pathol , vol.96 , pp. 95-99
    • Wu, S.S.1    Brady, K.2    Anderson, J.J.3    Vezina, R.4    Skinner, M.5    Neiman, R.S.6
  • 10
    • 0344172816 scopus 로고    scopus 로고
    • The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients
    • Perfetti V, Colli Vignarelli M, Anesi E, Garini P, Quaglini S, Ascari E, et al. The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. Haematologica 1999;84:218-221.
    • (1999) Haematologica , vol.84 , pp. 218-221
    • Perfetti, V.1    Colli Vignarelli, M.2    Anesi, E.3    Garini, P.4    Quaglini, S.5    Ascari, E.6
  • 11
    • 0032525180 scopus 로고    scopus 로고
    • Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients
    • Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients. Blood 1998;91:3662-3670.
    • (1998) Blood , vol.91 , pp. 3662-3670
    • Comenzo, R.L.1    Vosburgh, E.2    Falk, R.H.3    Sanchorawala, V.4    Reisinger, J.5    Dubrey, S.6
  • 12
    • 7144251173 scopus 로고    scopus 로고
    • Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: A report on 21 patients
    • Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: A report on 21 patients. Br J Haematol 1998;101:766-769.
    • (1998) Br J Haematol , vol.101 , pp. 766-769
    • Moreau, P.1    Leblond, V.2    Bourquelot, P.3    Facon, T.4    Huynh, A.5    Caillot, D.6
  • 13
    • 0005703329 scopus 로고    scopus 로고
    • Symposium on amyloid cardiomyopathy: Diagnosis and treatment, Pavia, September 21, 1996
    • Merlini G. Symposium on amyloid cardiomyopathy: Diagnosis and treatment, Pavia, September 21, 1996. Amyloid 1997;4:296-299.
    • (1997) Amyloid , vol.4 , pp. 296-299
    • Merlini, G.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.